Favipiravir effectiveness in patients undergoing COVID19 Acute respiratory distress syndrome (ARDS)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150107020592N26

Enrollment

Registered

2020-06-15

Start date

2020-03-20

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid positive. Coronavirus infection, unspecified

Interventions

Intervention group:Patients with a pao2 to fio2 ratio of less than 300 and who have bilateral infiltration in the chest x ray were included in the study. On the first day, 3200 mg for first day and 16

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Positive covid patients Patients with a pao2 to fio2 ratio below 300 Age over 18 years

Exclusion criteria

Exclusion criteria: Lack of desire to enter the plan

Design outcomes

Secondary

Measure	Time frame
Mortality. Timepoint: Completion of treatment. Method of measurement: death.	—

Primary

Measure	Time frame
Oxygenation. Timepoint: Up to 10 consecutive days. Method of measurement: pulse Oximetry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammad Reza Hashemian

Shahid Beheshti University of Medical Sciences

smrhashemian@sbmu.ac.ir+98 21 2610 9512

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026